Literature DB >> 25628947

Myelomatous plasma cells display an aberrant gene expression pattern similar to that observed in normal memory B cells.

Alicia Báez1, José I Piruat1, Teresa Caballero-Velázquez1, Luís I Sánchez-Abarca1, Isabel Álvarez-Laderas1, M Victoria Barbado1, Estefanía García-Guerrero1, África Millán-Uclés1, Jesús Martín-Sánchez1, Mayte Medrano1, José Antonio Pérez-Simón1.   

Abstract

Memory B cells (MBCs) remain in a quiescent state for years, expressing pro-survival and anti-apoptotic factors while repressing cell proliferation and activation genes. During their differentiation into plasma cells (PCs), their expression pattern is reversed, with a higher expression of genes related to cell proliferation and activation, and a lower expression of pro-survival genes. To determine whether myelomatous PCs (mPCs) share characteristics with normal PCs and MBCs and to identify genes involved in the pathophysiology of multiple myeloma (MM), we compared gene expression patterns in these three cell sub-types. We observed that mPCs had features intermediate between those of MBCs and normal PCs, and identified 3455 genes differentially expressed in mPCs relative to normal PCs but with a similar expression pattern to that in MBCs. Most of these genes are involved in cell death and survival, cell growth and proliferation and protein synthesis. According to our findings, mPCs have a gene expression pattern closer to a MBC than a PC with a high expression of genes involved in cell survival. These genes should be physiologically inactivated in the transit from MBC to PC, but remain overexpressed in mPCs and thus may play a role in the pathophysiology of the disease.

Entities:  

Keywords:  Gene expression; cell survival; memory B cells; multiple myeloma; plasma cells

Year:  2014        PMID: 25628947      PMCID: PMC4300706     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  50 in total

1.  The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells.

Authors:  Zainab Jagani; Dmitri Wiederschain; Alice Loo; Dan He; Rebecca Mosher; Paul Fordjour; John Monahan; Michael Morrissey; Yung-Mae Yao; Christoph Lengauer; Markus Warmuth; William R Sellers; Marion Dorsch
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Cancer stem cells in multiple myeloma.

Authors:  Nilanjan Ghosh; William Matsui
Journal:  Cancer Lett       Date:  2008-09-21       Impact factor: 8.679

Review 3.  The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma.

Authors:  Jie Li; Jingyu Zhu; Biyin Cao; Xinliang Mao
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 4.  The immortality of humoral immunity.

Authors:  Raul Elgueta; Victor C de Vries; Randolph J Noelle
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

5.  A novel NDUFA1 mutation leads to a progressive mitochondrial complex I-specific neurodegenerative disease.

Authors:  Prasanth Potluri; Antonio Davila; Eduardo Ruiz-Pesini; Dan Mishmar; Sean O'Hearn; Saege Hancock; Mariella Simon; Immo E Scheffler; Douglas C Wallace; Vincent Procaccio
Journal:  Mol Genet Metab       Date:  2009-01-29       Impact factor: 4.797

Review 6.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

7.  Identification of a novel t(7;14) translocation in multiple myeloma resulting in overexpression of EGFR.

Authors:  Brian A Walker; Christopher P Wardell; Fiona M Ross; Gareth J Morgan
Journal:  Genes Chromosomes Cancer       Date:  2013-06-13       Impact factor: 5.006

8.  Increased serum level of RPMPS-1/S27 protein in patients with various types of cancer is useful for the early detection, prevention and therapy.

Authors:  J Alberto Fernandez-Pol
Journal:  Cancer Genomics Proteomics       Date:  2012 Jul-Aug       Impact factor: 4.069

Review 9.  Pax5: the guardian of B cell identity and function.

Authors:  César Cobaleda; Alexandra Schebesta; Alessio Delogu; Meinrad Busslinger
Journal:  Nat Immunol       Date:  2007-05       Impact factor: 25.606

10.  Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study.

Authors:  Ivyna Bong Pau Ni; Ng Ching Ching; Chang Kian Meng; Zubaidah Zakaria
Journal:  Hematol Rep       Date:  2012-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.